Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by dt_coreon Feb 27, 2013 4:34pm
273 Views
Post# 21051160

RE: RE: RE: Hemisphere GPS appoints Dittmer as CFO

RE: RE: RE: Hemisphere GPS appoints Dittmer as CFO

It really feels like the board wanted to hit the reset button and disassociate as much as possible with the prior legacy/management of Hemisphere GPS with the intention of starting fresh and providing the company a new platform to finally build shareholder value. As such we've seen a significant change in management, corporate strategy, and even company name. The past has been swept under the rug.

 

I am disappointed that management did not provide guidance at the very least for the year. Having said that with a new team in place it makes sense for everyone to take stock of their contribution to the business and formulate a "real/feasible" business plan vs. throwing numbers at a dart board, which frankly is what the perception is of past management. SK's annual "25% growth" target sans strategy had many investors this year simply rolling their eyes, and when that proved to be materially corrected, even now coming in below 10% growth (non-core and core combined though. The ag division which remains had a decent year), all credibility was lost. Thankfully those days are over.

 

 

As an aside, very interesting to see the new Agjunction website. I still think it needs work but vastly improved over the beta version. What's interesting is the product line. Seems like RH wants to streamline the offerings (reduce skews). Not officially released, but the outback STX appears to be a much more durable version of the S3.

Bullboard Posts